Dexcom Joins FDA’s TEMPO Digital Health Devices Pilot Program
Dexcom has been selected as the first participant in the FDA’s TEMPO Pilot Program, which aims to evaluate digital health technologies that enhance chronic disease management and generate real-world evidence.
SAN DIEGO–(BUSINESS WIRE)–Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom